1. Home
  2. CHH vs GKOS Comparison

CHH vs GKOS Comparison

Compare CHH & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHH
  • GKOS
  • Stock Information
  • Founded
  • CHH 1939
  • GKOS 1998
  • Country
  • CHH United States
  • GKOS United States
  • Employees
  • CHH N/A
  • GKOS N/A
  • Industry
  • CHH Hotels/Resorts
  • GKOS Medical/Dental Instruments
  • Sector
  • CHH Consumer Discretionary
  • GKOS Health Care
  • Exchange
  • CHH Nasdaq
  • GKOS Nasdaq
  • Market Cap
  • CHH 5.8B
  • GKOS 5.1B
  • IPO Year
  • CHH 1997
  • GKOS 2015
  • Fundamental
  • Price
  • CHH $126.71
  • GKOS $94.31
  • Analyst Decision
  • CHH Hold
  • GKOS Strong Buy
  • Analyst Count
  • CHH 14
  • GKOS 13
  • Target Price
  • CHH $133.64
  • GKOS $135.15
  • AVG Volume (30 Days)
  • CHH 468.6K
  • GKOS 914.5K
  • Earning Date
  • CHH 05-08-2025
  • GKOS 04-30-2025
  • Dividend Yield
  • CHH 0.91%
  • GKOS N/A
  • EPS Growth
  • CHH 40.19
  • GKOS N/A
  • EPS
  • CHH 6.57
  • GKOS N/A
  • Revenue
  • CHH $797,663,000.00
  • GKOS $404,523,000.00
  • Revenue This Year
  • CHH $101.22
  • GKOS $27.89
  • Revenue Next Year
  • CHH $3.71
  • GKOS $27.57
  • P/E Ratio
  • CHH $19.29
  • GKOS N/A
  • Revenue Growth
  • CHH N/A
  • GKOS 23.92
  • 52 Week Low
  • CHH $109.46
  • GKOS $77.10
  • 52 Week High
  • CHH $157.86
  • GKOS $163.71
  • Technical
  • Relative Strength Index (RSI)
  • CHH 47.24
  • GKOS 50.08
  • Support Level
  • CHH $126.52
  • GKOS $93.52
  • Resistance Level
  • CHH $130.96
  • GKOS $101.57
  • Average True Range (ATR)
  • CHH 2.89
  • GKOS 3.33
  • MACD
  • CHH -0.00
  • GKOS 0.40
  • Stochastic Oscillator
  • CHH 30.60
  • GKOS 42.24

About CHH Choice Hotels International Inc.

As of Dec. 31, 2024, Choice Hotels operated 654,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (26% of the company's total domestic rooms), while Ascend and Cambria (10% of total domestic rooms) are newer lifestyle and select-service brands. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represent 78% of total rooms in 2024.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: